News
ZVRA
5.16
-0.29%
-0.02
*Zevra Therapeutics: Cash Runway Into 2026 >ZVRA
Dow Jones · 18h ago
ZEVRA THERAPEUTICS INC <ZVRA.O> Q1 SHR VIEW $-0.48 -- LSEG IBES DATA
Reuters · 18h ago
Press Release: Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates. Full commercial launch of OLPRUVA at the end of January 2024, with market access growing to 75% of covered lives as of May 1, 2024 Arimoclomol NDA review underway with PDUFA date of September 21, 2024 Reported positive topline results from KP1077 Phase 2 Trial in idiopathic hypersomnia.
Dow Jones · 18h ago
Press Release: Zevra Therapeutics Reports First -2-
OLPRUVA can cause serious side effects, including nervous system problems. Tell your doctor right away if you or your child get any of these symptoms. Your doctor may do certain blood tests to check for side effects. The most common side effects of OLPRU VA include absent or irregular menstrual periods.
Dow Jones · 18h ago
Zevra Therapeutics Q1 2024 Earnings Preview
Seeking Alpha · 1d ago
Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates
NASDAQ · 1d ago
When Will Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Become Profitable?
Zevra Therapeutics, Inc. Discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company posted a loss of US$46m in its most recent financial year. ZevraTherapeutics is expected to turn a profit in 2026. An average annual growth rate of 64% is expected for the company to reach breakeven.
Simply Wall St · 1d ago
Weekly Report: what happened at ZVRA last week (0429-0503)?
Weekly Report · 2d ago
ZEVRA THERAPEUTICS’ PRESIDENT AND CHIEF EXECUTIVE OFFICER ISSUES LETTER TO STOCKHOLDERS HIGHLIGHTING RECENT KEY ACCOMPLISHMENTS AND OUTLOOK FOR 2024
Reuters · 04/29 11:30
Weekly Report: what happened at ZVRA last week (0422-0426)?
Weekly Report · 04/29 09:18
Weekly Report: what happened at ZVRA last week (0415-0419)?
Weekly Report · 04/22 09:16
ZEVRA THERAPEUTICS PRESENTS NEW DATA ON THE LONG-TERM SAFETY AND EFFICACY OF ARIMOCLOMOL AS A TREATMENT FOR NIEMANN-PICK DISEASE TYPE C AT THE SIMD 45TH ANNUAL MEETING
Reuters · 04/15 21:01
Weekly Report: what happened at ZVRA last week (0408-0412)?
Weekly Report · 04/15 09:15
Zevra Therapeutics: Strong Buy on Strategic Financing and Promising Drug Portfolio
TipRanks · 04/11 19:35
Zevra Therapeutics Bolsters Finance Strategy with $100M Loan
TipRanks · 04/10 12:02
Zevra Therapeutics retires existing debt with new $100M credit facility
Zevra Therapeutics retires existing debt with new $100M credit facility. The stock price moved 2.8% higher on Wednesday during pre-market trading. The company entered into a new credit facility of up to $100m in committed capital in three tranches.
Seeking Alpha · 04/10 12:01
ZEVRA THERAPEUTICS INC: HAS RETIRED ITS COMBINED EXISTING DEBT OF APPROXIMATELY $43.1M
Reuters · 04/10 11:30
Press Release: Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility. New credit facility provides $100 million in committed capital in three tranches. The Company has retired its combined existing debt of approximately $43.1 million.
Dow Jones · 04/10 11:30
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility
Zevra Therapeutics, Inc. Has entered into a new credit facility provided by leading biotech investors. New credit facility provides up to $100M in committed capital in three tranches. The Company has retired its combined existing debt of approximately $43.1M.
Barchart · 04/10 06:30
More
Webull provides a variety of real-time ZVRA stock news. You can receive the latest news about Zevra Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ZVRA
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA.